Amphastar Pharmaceuticals (AMPH) Cash from Financing Activities (2013 - 2026)

Amphastar Pharmaceuticals' Cash from Financing Activities history runs 14 years deep, the most recent figure standing at -$30.2 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 108.28% year-over-year to -$30.2 million in Q1 2026; TTM through Mar 2026 was -$83.1 million, a 1.53% decrease from a year earlier, with the FY2025 full-year figure at -$67.4 million, up 16.71% from the prior year.
• Cash from Financing Activities slipped to -$30.2 million in Q1 2026 per AMPH's latest filing, from -$18.4 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $428.1 million in Q2 2023 and bottomed at -$47.1 million in Q4 2023.
• The 5-year median for Cash from Financing Activities is -$13.9 million (2022), against an average of $14.7 million.
• Biggest YoY gain for Cash from Financing Activities was 43169.52% in 2023; the steepest drop was 391.48% in 2023.
• Year by year, Cash from Financing Activities stood at -$16.2 million in 2022, then tumbled by 191.32% to -$47.1 million in 2023, then rose by 28.12% to -$33.8 million in 2024, then jumped by 45.71% to -$18.4 million in 2025, then tumbled by 64.41% to -$30.2 million in 2026.
• Per Business Quant, the three latest AMPH Cash from Financing Activities figures stand at -$30.2 million (Q1 2026), -$18.4 million (Q4 2025), and -$4.3 million (Q3 2025).